Human HLA-A*01:01&B2M&DSG3 (YTDNWLAVY) Monomer Protein





Description	
Source	Recombinant Human HLA-A*01:01&B2M&DSG3 (YTDNWLAVY) Monomer Protein is expressed from HEK293 with His tag and Avi Tag at the C-Terminus.
	It contains Gly25-Thr305(HLA-A*01:01), Ile21-Met119(B2M) and YTDNWLAVY peptide
Accession	Q5SUL5(HLA-A*01:01)&P61769(B2M)&YTDNWLAVY
Molecular Weight	The protein has a predicted MW of 50.50 kDa. Due to glycosylation, the protein migrates to 52-62 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 1EU per μg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE
	> 95% as determined by HPLC

Formulation and Storage


Formulation	Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt80°C for 3 months after reconstitution.Recommend

Background

DSG3 is overexpressed in head neck cancer and is a potential molecular target for inhibition of oncogenesis. DSG3 is identified overexpressed in HNC, with the degree of overexpression associated with clinicopathologic features of the tumor. Inhibition of DSG3 significantly suppresses carcinogenic potential in cellular and in vivo animal studies. These findings suggest that DSG3 is a potential molecular target in the development of adjuvant therapy for HNC.


Assay Data

Bis-Tris PAGE



Human HLA-A*01:01&B2M&DSG3 (YTDNWLAVY) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC



The purity of Human HLA-A*01:01&B2M&DSG3 (YTDNWLAVY) Monomer is greater than 95% as determined by SEC-HPLC.